{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:26:41Z","timestamp":1778826401284,"version":"3.51.4"},"reference-count":0,"publisher":"Hindawi Limited","issue":"8","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Gastroenterology"],"published-print":{"date-parts":[[2008]]},"abstract":"<jats:p>BACKGROUND: There is little published information on baseline characteristics and therapeutic outcomes in hepatitis C virus (HCV)-infected Aboriginal Canadians. It is unclear what proportion of HCV-infected Aboriginal people receive therapy relative to other populations.<\/jats:p><jats:p>METHODS: Adults with chronic HCV infection, quantifiable serum HCV-RNA levels and compensated liver disease were assigned, at the physician\u2019s discretion, to either 24 or 48 weeks of treatment with peginterferon alpha-2a 180 \u03bcg\/week plus ribavirin at a dose of 800 mg\/day, or 1000 mg\/day or 1200 mg\/day in an open-label, expanded access program. The primary outcome was sustained virological response, defined as undetectable HCV-RNA by qualitative polymerase chain reaction (less than 50 IU\/mL) at the end of 24 weeks of untreated follow-up. Baseline characteristics and outcomes in Aboriginal and non-Aboriginal patients were compared.<\/jats:p><jats:p>RESULTS: A total of 2614 patients were eligible for the analysis; 44 individuals (1.7%) self-identified as being of Aboriginal heritage. The baseline characteristics of these two groups were similar. An overall sustained virological response was achieved in 47.7% and 46.5% of Aboriginal and non-Aboriginal patients, respectively. The overall frequencies of adverse events and laboratory abnormalities were similar between the two groups, although cytopenias occurred less frequently in Aboriginal patients.<\/jats:p><jats:p>INTERPRETATION: Aboriginal patients were greatly under-represented in the present \u2018community\u2019-based treatment program, yet viral responses were similar to those of a non-Aboriginal cohort. To increase the uptake of HCV therapy in the Aboriginal population, clarification of the obstacles to treatment is warranted.<\/jats:p>","DOI":"10.1155\/2008\/320150","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T03:53:52Z","timestamp":1458014032000},"page":"677-680","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of Peginterferon Alpha-2a and Ribavirin Hepatitis C therapy in Aboriginal Canadians"],"prefix":"10.1155","volume":"22","author":[{"given":"Curtis L","family":"Cooper","sequence":"first","affiliation":[{"name":"University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J","family":"Bailey","sequence":"additional","affiliation":[{"name":"Royal Alexandra Hospital, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vince G","family":"Bain","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Anderson","sequence":"additional","affiliation":[{"name":"The Liver and Intestinal Research Centre, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Vancouver Hospital Health Sciences Centre, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mel","family":"Krajden","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Marotta","sequence":"additional","affiliation":[{"name":"University of Western Ontario, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"for the Canadian Pegasys Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","container-title":["Canadian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2008\/320150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2008\/320150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T04:05:42Z","timestamp":1471925142000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/cjgh\/2008\/320150\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008]]}},"alternative-id":["320150"],"URL":"https:\/\/doi.org\/10.1155\/2008\/320150","relation":{},"ISSN":["0835-7900"],"issn-type":[{"value":"0835-7900","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}